Highlights

  • Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) has published 2026 company and financial updates.
  • Reported revenue: NZD 2.31 billion.
  • Reported earnings: net profit after tax of NZD 468.5 million.
  • The company has a 31 March financial year end.

Fisher & Paykel Healthcare Corporation Limited, listed as (ASX:FPH), operates in respiratory care, acute care and sleep-related medical devices. The business has reported developments during 2026 concerning its operations, financial position and near-term priorities. On 21 October 2026, Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) was quoted at AUD 39.905, with a daily change of +0.01% for the trading session. Its recent disclosures provide a basis for assessing reported activity without attributing the daily price movement to any particular announcement.

Company Business

The core operations of Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) span internationally through its Hospital and Homecare product groups. Its devices include heated humidification systems, breathing circuits, interfaces and related consumables used in hospital respiratory therapies and home treatment. This portfolio exposes the company to procurement decisions, healthcare budgets and clinical or consumer demand in its operating markets. The reported financial performance depends not only on sales volumes, but also on product mix, service delivery requirements and operating expenses. The company's activities should therefore be considered through both its operating disclosures and its detailed financial reporting.

Recent Development

In May 2026 the company released results for the year ended 31 March 2026. Constant-currency total revenue growth was 12%; reported Hospital revenue growth was 18%. Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) has continued to report business activity through official investor communications. The company has a 31 March financial year end. Such developments are distinct from the daily market quotation and should be considered against the timing and scope described in each company release. Operational initiatives also require ongoing execution, and announced projects should not be treated as completed until the relevant company confirms delivery.

Financial Performance and Sector Context

For its latest published 2026 reporting period, Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) disclosed revenue of NZD 2.31 billion. It also reported net profit after tax of NZD 468.5 million. Additional financial information included annual revenue growth of 14% and net profit growth of 24%. Hospital product group revenue was NZD 1.51 billion, up 18%, while hospital consumables sales increased 16%. These figures reflect the company's own reporting definitions, and adjustments labelled underlying or normalised should not be confused with statutory results. Healthcare demand can differ across products and geographies, while reimbursement decisions and currency changes may affect reported outcomes. Monitoring the relationship between sales, operating expenditure and cash conversion remains important when comparing reporting periods.

Risks to Consider

Business and industry risks for Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) include Hospital procurement cycles, changing respiratory admissions, manufacturing capacity, product approvals, currency translation and reimbursement policy. Commercial contracts and clinical products can be affected by regulatory approvals, purchasing cycles or changes in provider capacity. Even where sales are recurring, cost inflation and implementation spending can alter profitability. Overseas operations may also introduce foreign exchange translation differences. The materiality of each risk will depend on the company's latest operational experience and the financial information it releases. Risks should be distinguished from confirmed adverse outcomes; an exposure does not establish that a loss will occur.

What to Watch Next

Future disclosures from Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) may clarify The results for the six months ending September 2026, due to be reported subsequently, and trends in hospital consumables and Homecare demand. The next results statement may also indicate whether announced initiatives are reflected in operating margins, cash flow or capital expenditure. Readers can compare management's stated plans with completed activities and monitor how changes in service demand, procurement and pricing appear in official releases. Dates for meetings, reporting and other milestones should be checked against any later corporate announcements rather than assumed to remain unchanged.

Key Insights

Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) combines its established operating activities with developments reported during 2026. Its most recent official results and statements provide information about earnings, business priorities and identifiable operating risks. The market quotation for 21 October is a separate trading observation and does not establish a cause for price movement. Subsequent company disclosures will be relevant for assessing progress on operational initiatives, financial performance and the use of capital. Any interpretation should preserve the distinction between reported results, management targets and outcomes that have not yet occurred.